Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-α-transgenic mice
SC Wentz, H Wu, MT Yip-Schneider, M Hennig… - Journal of …, 2008 - Elsevier
Abstract Hepatocellular carcinoma (HCC) causes 600,000 mortalities per year worldwide.
Previous studies from our lab provide evidence for altered mitogen-activated protein kinase
and extracellular signal-regulated kinase kinase (MEK) signaling in HCC pathogenesis. We
hypothesized that pharmacologic targeting of MEK may prevent HCC. Transforming growth
factor-alpha-transgenic mice (CD1-MT42) exposed to diethylnitrosamine were randomized
to 20 (trial I) or 35 (trial II) weeks of MEK inhibitor PD0325901 (1, 10 mg/kg) or control via …
Previous studies from our lab provide evidence for altered mitogen-activated protein kinase
and extracellular signal-regulated kinase kinase (MEK) signaling in HCC pathogenesis. We
hypothesized that pharmacologic targeting of MEK may prevent HCC. Transforming growth
factor-alpha-transgenic mice (CD1-MT42) exposed to diethylnitrosamine were randomized
to 20 (trial I) or 35 (trial II) weeks of MEK inhibitor PD0325901 (1, 10 mg/kg) or control via …